Clinical Significance of F/T PSA Ratio in Advanced Prostate Cacner 153 prostate cancer 2. Radiotherapy, neoadjuvanct endocrine treat- ment, update 1997-1999. World J Urol 2000;18:204-15. 17. Rosenthal SA, Sandler HM. Treatment strategies for high-risk locally advanced prostate cancer. Nat Rev Urol 2010;7:31-8. 18. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part I: Screening, di- agnosis, and treatment of clinically localised disease. Eur Urol 2011;59:61-71. 19. Heidenreich A. Current approach to androgen deprivation ther- apy in patients with advanced prostate cancer. Eur Urol Suppl 2010;9:776-81. 20. Huang SP, Bao BY, Wu MT, Choueiri TK, Goggins WB, Huang CY, et al. Impact of prostate-specific antigen (PSA) nadir and time to PSA nadir on disease progression in prostate cancer treated with androgen-deprivation therapy. Prostate 2011;71:1189-97. 21. Collette L, Burzykowski T, Schröder FH. Prostate-specific anti- gen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials. Eur J Cancer 2006;42:1344-50. 22. Yoon CY. Free PSA and the free PSA to total PSA ratio as predictor of response to hormone treatment for metastatic prostate cancer. Korean J Urol 2006;47:362-7. 23. Tanaka M, Murakami S, Suzuki N, Shimazaki J. Change in the ratio of free-to-total prostate-specific antigen during progression of advanced prostate cancer. Int J Urol 2000;7:83-7. Korean J Urol 2012;53:149-153